 |
|
Prospective Study of Tardive Dyskinesia Incidence in the Elderly
Bruce L. Saltz, MD;
Margaret G. Woerner, PhD;
John M. Kane, MD;
Jeffrey A. Lieberman, MD;
Jose Ma. J. Alvir, DrPH;
Kenneth J. Bergmann, MD;
Karen Blank, MD;
Jonathan Koblenzer, MD;
Kenneth Kahaner, MD
JAMA. 1991;266(17):2402-2406.
Abstract
| |
Objectives.
—To investigate the incidence of tardive dyskinesia in elderly individuals beginning treatment with antipsychotic drugs and to identify risk factors for the development of tardive dyskinesia in the elderly.
Design.
—A cohort of previously neuroleptic-naive patients was identified at the time of initiation of antipsychotic drug treatment. Patients were evaluated at baseline and followed up at 3-month intervals for periods ranging from 3 to 119 weeks.
Setting.
—Subjects were recruited from the psychiatric and geriatric medical services of two medical centers, a geriatric institute, and three nursing homes in the metropolitan area of New York City, NY.
Patients.
—Two hundred fifteen individuals older than 55 years have entered the study thus far. Preliminary data are presented for 160 patients who were followed up for at least 1 month. Their age range was 57 to 99 years (mean, 77 years). Seventy-two percent were women and 87% were white. Sixty-seven percent of patients had a diagnosis of organic mental syndrome and 42% had a psychiatric diagnosis.
Interventions.
—A naturalistic, longitudinal, repeated assessment paradigm was employed. Assessments included abnormal involuntary movements, extrapyramidal signs, psychiatric symptoms, and medical and drug treatment histories.
Main Outcome Measure.
—The incidence of tardive dyskinesia was determined using a standardized rating instrument and survival analysis.
Results.
—The incidence of neuroleptic-induced dyskinesia was 31% (95% confidence interval, 20%, 42%) after 43 weeks of cumulative neuroleptic treatment. Psychiatric (as opposed to organic) diagnosis and presence of extrapyramidal signs early in treatment were associated with increased tardive dyskinesia vulnerability.
(JAMA. 1991;266:2402-2406)
Author Affiliations
From the Department of Psychiatry, Hillside Hospital, Long Island Jewish Medical Center, Glen Oaks, NY (Drs Saltz, Woerner, Kane, Lieberman, Alvir, and Kahaner); the Department of Neurology, Long Island Jewish Medical Center (Dr Bergmann); the Parker Jewish Geriatric Center, New Hyde Park, NY (Dr Kahaner); Albert Einstein College of Medicine, Bronx, NY (Drs Saltz, Woerner, Kane, Lieberman, and Bergmann); and Department of Psychiatry, Beth Israel Medical Center, New York, NY (Drs Blank and Koblenzer).
Footnotes
Reprint requests to Department of Psychiatry, Hillside Hospital, Box 38, Glen Oaks, NY 11004 (Dr Saltz).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Extrapyramidal side-effects of antipsychotics in a randomised trial
Miller et al.
Br. J. Psychiatry 2008;193:279-288.
ABSTRACT
| FULL TEXT
Antipsychotic Medication Use in the Elderly Patient
Malone et al.
Journal of Pharmacy Practice 2007;20:318-326.
ABSTRACT
Pharmacotherapy for behavioral and psychological symptoms of dementia in the elderly
Beier
Am J Health Syst Pharm 2007;64:S9-S17.
ABSTRACT
| FULL TEXT
Evidence That Early Extrapyramidal Symptoms Predict Later Tardive Dyskinesia: A Prospective Analysis of 10,000 Patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) Study
Tenback et al.
Am. J. Psychiatry 2006;163:1438-1440.
ABSTRACT
| FULL TEXT
Acute Dystonic Reaction and the Neuroleptic Malignant Syndrome
White
Journal of Pharmacy Practice 2005;18:175-187.
ABSTRACT
Dr. Correll and Colleagues Reply
CORRELL et al.
Am. J. Psychiatry 2005;162:405-406.
FULL TEXT
Physical Health Monitoring of Patients With Schizophrenia
Marder et al.
Am. J. Psychiatry 2004;161:1334-1349.
ABSTRACT
| FULL TEXT
Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies
Correll et al.
Am. J. Psychiatry 2004;161:414-425.
ABSTRACT
| FULL TEXT
Incidence of Tardive Dyskinesia in Early Stages of Low-Dose Treatment With Typical Neuroleptics in Older Patients
Jeste et al.
Am. J. Psychiatry 1999;156:309-311.
ABSTRACT
| FULL TEXT
Prospective Study of Tardive Dyskinesia in the Elderly: Rates and Risk Factors
Woerner et al.
Am. J. Psychiatry 1998;155:1521-1528.
ABSTRACT
| FULL TEXT
Incidence and Correlates of Tardive Dyskinesia in First Episode of Schizophrenia
Chakos et al.
Arch Gen Psychiatry 1996;53:313-319.
ABSTRACT
Risk of Tardive Dyskinesia in Older Patients: A Prospective Longitudinal Study of 266 Outpatients
Jeste et al.
Arch Gen Psychiatry 1995;52:756-765.
ABSTRACT
Duration of Neuroleptic Treatment and Prevalence of Tardive Dyskinesia in Late Life
Sweet et al.
Arch Gen Psychiatry 1995;52:478-486.
ABSTRACT
Neuroleptic Withdrawal in Schizophrenic Patients: A Review of the Literature
Gilbert et al.
Arch Gen Psychiatry 1995;52:173-188.
ABSTRACT
Neuropsychological Deficits in Schizophrenics: Relationship to Age, Chronicity, and Dementia
Heaton et al.
Arch Gen Psychiatry 1994;51:469-476.
ABSTRACT
TARDIVE DYSKINESIA IS COMMON AFTER NEUROLEPTIC THERAPY IN THE ELDERLY
JWatch General 1991;1991:1-1.
FULL TEXT
|
